Amedisys AI Visibility Market Strategy Report - Home Health Care

Answer Capsule

Amedisys holds a small but measurable position in AI-generated home health care recommendations, with a 4.05% valid recommendation coverage rate in October 2026. The brand is visible in 11.21% of qualified observations but converts that presence into a valid recommendation only about a third of the time, indicating a substantial recommendation gap. Its strongest signal appears on Google AI Mode, where it captured 7 valid recommendations, while its weakest performance is on Perplexity and ChatGPT, where it recorded zero valid recommendations. The clearest opportunity lies in converting its existing presence into top-three placements, particularly given that its average recommended rank of 3.46 is competitive when it does appear.

Who This Report Is For

This report is written for Amedisys marketing, communications, and strategy leaders who need to understand how AI systems are positioning the brand in home health care recommendation contexts, and where the clearest gaps and opportunities exist relative to competitors.

Report Card

Executive Summary

Amedisys is visible in AI-generated home health care answers but is not consistently recommended. The brand appeared in 36 of 321 qualified observations in October 2026, a raw mention presence rate of 11.21%, yet it received valid recommendation credit in only 13 observations, a valid recommendation coverage rate of 4.05%. This means that when Amedisys is mentioned, it is not always included in the recommendation shortlist that AI systems present to buyers.

The brand's recommendation position is modest but not without merit. Amedisys recorded 21 positive mentions, 15 neutral mentions, and zero negative mentions, producing a net sentiment score of 0.5833. That score is the lowest among the top eight tracked brands, suggesting that while Amedisys is not being framed negatively, it is also not being framed as positively as competitors like Visiting Angels, Home Instead, or Comfort Keepers.

Amedisys' strongest platform signal comes from Google AI Mode, where it captured 7 valid recommendations and a 6.67% valid recommendation coverage rate. Google AI Overviews also contributed 3 valid recommendations. However, the brand recorded zero valid recommendations on Perplexity and ChatGPT, and only 1 valid recommendation on Copilot, indicating significant platform-specific gaps.

The brand's average recommended rank of 3.46 is competitive when it does appear in a recommendation shortlist, but its top-three rate of 2.49% and rank-one rate of 1.25% are both low. Amedisys is being recommended, but rarely in the first or second position that would place it at the front of a buyer shortlist.

The clearest gap is the conversion from presence to recommendation. Amedisys appears in 11.21% of qualified observations but receives valid recommendation credit in only 4.05%. Competitors like Visiting Angels convert 82.55% presence into 66.98% recommendation coverage, and Home Instead converts 70.09% presence into 56.70% recommendation coverage. Amedisys is being mentioned without being chosen.

The biggest opportunity for Amedisys is to improve its recommendation conversion rate on the platforms where it already has a presence, particularly Google AI Mode and Google AI Overviews, while addressing the complete absence of valid recommendations on Perplexity and ChatGPT.

What Amedisys Is Winning

Questions This Section Answers

• On which AI platform does Amedisys perform best, and what makes it the strongest signal?
• What is Amedisys' current average recommended rank when it appears in a shortlist?

Amedisys has a measurable presence in AI-generated home health care answers, appearing in 36 of 321 qualified observations. That presence is not negligible, and it provides a foundation on which recommendation coverage can be built.

The brand's strongest platform by recommendation behavior is Google AI Mode, where it recorded 7 valid recommendations and a 6.67% valid recommendation coverage rate. This is the only platform where Amedisys achieved a recommendation coverage rate above 5%, and it represents the clearest pocket of recommendation strength for the brand.

Amedisys also benefits from a complete absence of negative framing. The brand recorded zero negative mentions across all platforms, which means that when AI systems mention Amedisys, they are not associating the brand with cautionary or unfavorable language. This is a meaningful baseline, even if the brand is not yet being recommended as frequently as competitors.

The brand's average recommended rank of 3.46 is competitive. When Amedisys does receive a valid recommendation, it typically appears in the third or fourth position, which places it within the consideration set even if it is not at the front of the shortlist.

Where Amedisys Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does Amedisys appear in AI answers but fail to earn a recommendation?
• Which platforms produce zero valid recommendations for Amedisys despite mentions?
• How far behind are Amedisys' top-three and rank-one rates compared to category leaders?

The most significant gap for Amedisys is the disconnect between presence and recommendation. The brand appears in 11.21% of qualified observations but receives valid recommendation credit in only 4.05%. This means that in the majority of cases where Amedisys is mentioned, it is not included in the recommendation shortlist that AI systems present to buyers.

This gap is most pronounced on Perplexity and ChatGPT, where Amedisys recorded zero valid recommendations despite appearing in 2 and 2 observations respectively. On Copilot, the brand recorded only 1 valid recommendation from 9 mentions. These platforms represent a significant portion of the AI search surface, and Amedisys is effectively absent from recommendation consideration on them.

The brand's top-three rate of 2.49% and rank-one rate of 1.25% are both low relative to competitors. Visiting Angels recorded a top-three rate of 57.01% and a rank-one rate of 15.26%, while Home Instead recorded 44.86% and 18.69% respectively. Amedisys is not competing for the first or second recommendation position in most cases.

The brand's net sentiment score of 0.5833 is the lowest among the top eight tracked brands. While this does not indicate negative framing, it does suggest that Amedisys is being described in more neutral or factual terms than competitors, which may reduce its perceived recommendation strength.

Amedisys also faces a competitive displacement challenge. The benchmark shows that Visiting Angels, Home Instead, Comfort Keepers, and Right at Home collectively dominate recommendation coverage, with each recording valid recommendation coverage above 45%. Amedisys, at 4.05%, is significantly behind this leading tier.

Biggest Opportunity

Questions This Section Answers

• Which platforms offer Amedisys the strongest foundation for improving recommendation coverage?
• How can Amedisys move from third or fourth position into the top three in buyer shortlists?

The clearest opportunity for Amedisys is to improve its recommendation conversion rate on Google AI Mode and Google AI Overviews, the two platforms where it already has a measurable recommendation presence. Google AI Mode contributed 7 valid recommendations and Google AI Overviews contributed 3, accounting for 10 of the brand's 13 total valid recommendations. These platforms represent the strongest existing foundation for recommendation growth.

The specific opportunity is to move from being mentioned to being recommended in the top three positions. Amedisys' average recommended rank of 3.46 indicates that when it is recommended, it is typically in the third or fourth position. Improving that to the second or third position would increase its top-three rate and place the brand more prominently in buyer shortlists.

This opportunity is tied to the Brand Recommendation cluster, which is the only qualified cluster in the October 2026 benchmark. The prompts in this cluster ask which home health care provider to choose, and Amedisys needs to be positioned as a first-choice recommendation rather than a secondary mention.

Competitive Landscape

Questions This Section Answers

• Where does Amedisys rank against competitors like Visiting Angels and Home Instead on top-three recommendation rate?
• Which brands dominate recommendation coverage in home health care, and how large is the gap to Amedisys?

Visiting Angels holds the strongest recommendation-stage position in the home health care category, with Home Instead and Comfort Keepers also demonstrating significant recommendation power. Amedisys sits in the lower tier of the tracked competitor set, with recommendation coverage well below the category leaders.

Average recommended rank covers rank-eligible recommendations only.

Amedisys ranks eighth out of ten tracked brands by top-three rate, ahead of only Addus HomeCare and Honor. The brand's rank-one rate of 1.25% is similarly low, indicating that Amedisys is rarely the first recommendation AI systems present. The gap between Amedisys and the category leaders is substantial, with Visiting Angels recording a top-three rate more than twenty times higher.

AI Response Inconsistency Alerts

Questions This Section Answers

• What conflicting information do AI platforms provide about Amedisys' ownership status?
• Where do platforms disagree about which company is the largest home health provider by patient volume?

AI platforms provided conflicting information about Amedisys across four critical and high-severity factual inconsistencies, involving four platforms: ChatGPT, Copilot, Gemini, and Google AI Mode. These conflicts center on the brand's ownership status and its ranking among home health care companies.

The most severe conflict concerns Amedisys' ownership status. When asked "Who is the largest home health company?", Google AI Mode stated that Amedisys was acquired by UnitedHealth Group's Optum, with the merger finalized in August 2025, citing Becker's Payer and LinkedIn posts. Copilot, responding to the same question, stated that Amedisys Inc. is an independent leader in home health and hospice care, citing Ampliz. These two claims cannot both be true, and the conflicting responses create uncertainty about Amedisys' corporate structure.

A second high-severity conflict also concerns ownership. When asked "What are the biggest home health companies?", Gemini described Amedisys as a leading national provider without stating it had been acquired, citing Agentically and ScrapeHero. ChatGPT, responding to the same question, stated that Amedisys is now owned by UnitedHealth Group, citing Healthcare DealHub, Definitive Healthcare, and a SEC filing. The two platforms provided contradictory information about whether Amedisys remains independent.

A third high-severity conflict concerns which company is largest by patient volume. When asked "What is the largest home health care company?", Copilot claimed that Amedisys is the largest home health care company by patient volume, serving over 2.5 million patients annually, citing Ampliz and ZoomInfo. Google AI Mode, responding to the same question, stated that Matrix Medical Network serves the largest total number of individual patients in the U.S. clinical and home-assessment space, citing Statista and Definitive Healthcare. Both companies cannot simultaneously be the largest by patient volume.

A fourth high-severity conflict concerns the largest home health company ranking. When asked "Who is the largest home health company?", Google AI Mode stated that UnitedHealth Group's Optum operates the largest combined home health platform, not Amedisys individually, citing Becker's Payer and LinkedIn posts. Copilot, responding to the same question, claimed that Amedisys Inc. is the largest home health company in the U.S. in 2026, citing Ampliz. These responses present fundamentally different views of Amedisys' market position.

These inconsistencies indicate that AI systems are drawing on conflicting sources when describing Amedisys, and that the brand's ownership status and market ranking are not consistently represented across platforms. This creates a risk that buyers receiving AI-generated recommendations may encounter contradictory information about Amedisys.

Prompt Evidence

Google AI Mode / Brand Recommendation Prompt: "Who is the largest home health company?" Result: Google AI Mode stated that UnitedHealth Group's Optum operates the largest combined home health platform, not Amedisys individually, while Copilot claimed Amedisys is the largest home health company in the U.S. in 2026.

Copilot / Brand Recommendation Prompt: "What is the largest home health care company?" Result: Copilot claimed Amedisys is the largest home health care company by patient volume, serving over 2.5 million patients annually, while Google AI Mode stated Matrix Medical Network serves the largest total number of individual patients.

Gemini / Brand Recommendation Prompt: "What are the biggest home health companies?" Result: Gemini described Amedisys as a leading national provider without stating it had been acquired, while ChatGPT stated Amedisys is now owned by UnitedHealth Group.

ChatGPT / Brand Recommendation Prompt: "Who is the largest home health company?" Result: ChatGPT provided no valid recommendation for Amedisys, and the brand recorded zero valid recommendations on this platform across all qualified observations.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map every prompt where Amedisys is mentioned but not recommended, and identify which competitors are taking the recommendation position instead.

Phase 2: Recommendation Readiness Plan Prioritize the Google AI Mode and Google AI Overviews prompts where Amedisys already has recommendation presence, and build a plan to move from third or fourth position into the top three.

Phase 3: Owned Answer Layer Buildout Develop owned content that directly addresses the Brand Recommendation prompts where Amedisys is currently absent from the shortlist, with clear positioning on ownership status and market ranking.

Phase 4: Citation / Authority Layer Development Strengthen the public evidence layer that AI systems draw on when forming recommendations, particularly the sources that platforms cite when describing Amedisys' ownership and market position.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track Amedisys' recommendation coverage, top-three rate, and rank-one rate month over month, with platform-level breakdowns to measure progress on Google AI Mode, Google AI Overviews, and the platforms where the brand is currently absent.

Why This Matters

AI systems are increasingly where buyers form their shortlist of home health care providers. When a family member or discharge planner asks an AI assistant which home health care company to choose, the answer they receive shapes their consideration set before they ever visit a website or make a call. Amedisys is currently being mentioned in those answers but is not consistently being recommended, which means the brand is visible without being chosen.

The inconsistency in how AI platforms describe Amedisys' ownership and market position adds a layer of risk. If some platforms describe Amedisys as an independent leader while others describe it as a subsidiary of UnitedHealth Group's Optum, buyers may receive conflicting signals about the brand's identity and stability. Correcting the prompt, page, and citation layers that feed these AI answers is the next step for improving both recommendation coverage and framing consistency.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Amedisys in October 2026, the calculation is: (21 × 1 + 15 × 0 + 0 × -1) / 36 = 0.5833.

This score matters because unclassified mention counts are misleading. A brand that is mentioned frequently but framed neutrally is not in the same position as a brand that is mentioned frequently and framed positively. Amedisys recorded 21 positive mentions and 15 neutral mentions, with zero negative mentions. The 15 neutral mentions represent cases where Amedisys was referenced as context, listed alongside other providers, or described in factual terms without a clear recommendation signal.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, and Amedisys' sentiment score of 0.5833 indicates that the brand is being framed positively more often than not, but less positively than competitors like Comfort Keepers (0.8702) or Home Instead (0.8533).

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Amedisys' AI visibility and recommendation performance in the home health care category, using data from the LLM Authority Index AI Visibility Market Discovery Index for October 2026.
2. The reporting window is October 2026, with comparisons to the July 2026 baseline where available.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Mode, and Google AI Overviews.
4. The analysis is based on 321 qualified observations from an initial collection of 800 prompt-surface observations. The qualification process removed 380 irrelevant observations and 97 reserved observations, leaving 321 qualified observations as the public denominator for all brand-level metrics.
5. The competitor universe includes ten tracked brands: Addus HomeCare, Amedisys, BAYADA Home Health Care, BrightStar Care, Comfort Keepers, Home Instead, Honor, Interim HealthCare, Right at Home, and Visiting Angels.
6. One public high-intent cluster was used: Brand Recommendation (C01), which captures queries asking which home health care provider to choose. Two additional clusters, Pricing and Value (C02) and Multi-Brand Comparison (C03), had no qualified observations in October 2026.
7. Stage 0 extraction was used to identify brand mentions, recommendation outcomes, ranking positions, sentiment, and citations from raw AI responses.
8. A mention is defined as any instance where Amedisys appears in an AI-generated response to a qualified prompt, regardless of whether the brand is recommended.
9. A valid recommendation is defined as an instance where Amedisys appears in a recommendation shortlist with a rank position of 1 through 10, as marked by the dataset.
10. The unique question count for October 2026 was 630, after de-duplication from the raw collection.
11. All percentages are calculated against the qualified benchmark set of 321 observations, not the raw collection universe.
12. Limitations: The public benchmark measures the Brand Recommendation cluster only and does not yet contain qualified pricing or comparison observations. Small-count movement for brands with few qualified observations can shift by several points with a handful of recommendation changes. The benchmark identifies where attention is warranted but does not establish causality.

See How AI Is Recommending Your Brand

Amedisys is visible in AI-generated home health care answers, but visibility alone does not secure a place on the buyer shortlist. A company-level AI visibility audit maps the specific prompts, platforms, competitors, and citation sources that shape how AI systems recommend your brand, and identifies the clearest path from mention to recommendation.